R&D-Innovation > Projets de R&D labellisés > Novel Therapies

Novel Therapies

  • DNAVac - Development and production of DNA vaccines without antibiotic resistance gene.

    Today vaccination is an uncontested way of fighting disease. DNA vaccination seems to be a particularly promising method at this time. For this application, plasmid DNA is injected into the subject (man or animal). This plasmid DNA encodes for an antigen that will be produced by the subject’s cells. In addition to the antigen, the plasmid also encodes for a resistance to an antibiotic used during the construction and production of the molecule. This resistance is increasingly less tolerated by the regulatory agencies (FDA and EMA). In the context of this project, we are proposing to replace this resistance to an antibiotic by a selection system based on bacterial genes that have already been used by Delphi Genetics for the production of proteins without an antibiotic-resistance gene. The project’s objective is threefold:1) To develop a technology enabling DNA vaccines to be formulated quickly and without antibiotic-resistance genes; 2) To obtain sufficient scientific data to constitute a file for FDA or USDA and EMA; 3) To proceed with at least three examples of effective DNA vaccines in the veterinary field.

  • Ovart - Assembly of an artificial ovary combining isolated human ovarian follicles, fibrin and a textile pocket.

    The objective of this project is the development of a 3D biodegradable matrix allowing the graft of autologous ovarian tissue or isolated follicles in patients with impaired fertility following a gonadotoxic treatment. This biofunctional fibrin-based matrix will limit the follicular loss due to post-transplant ischemic stress and will help to induce the formation of an extracellular ovarian-like matrix by promoting cell migration, cell proliferation and vascularization. In addition, a biodegradable textile pocket will also be developed to contain the tissue scaffold and to efficiently suture the graft at the implantation site.

  • STEMVAC - Innovative immunotherapy approaches for treating breast cancer patients.

    Breast cancer is the most common malignancy in women and ranks second as a cause of cancer death (after lung cancer). There is a clear medical need for breast cancer treatments associated with improved efficacy in term of control of distant recurrence, and with improved safety and tolerance profile. Active and Specific Cancer Immunotherapies hold these promises because they aim at inducing tumor-specific effects while sparing non-tumor, normal tissues. The Stemvac project aims at discovering new antigens associated with breast cancer stem cells using highly innovative research techniques. The research will result in the development of new immunotherapies against cancer.